Demodex blepharitis (DB) is a common yet frequently underrecognized condition, often misdiagnosed as dry eye disease or meibomian gland dysfunction, leading to delayed treatment and increased patient burden. Clinicians need improved recognition of hallmark signs such as collarettes, along with a clearer understanding of the limitations of traditional therapies and the role of newer evidence-based options like lotilaner. Enhancing diagnostic accuracy, individualized treatment selection, and structured follow-up can improve adherence and long-term outcomes. Education focused on these strategies aims to reduce misclassification, optimize care, and improve quality of life for patients with DB.

*Please stay tuned for additional content to this activity available for credit. The maximum amount of credit(s) available for the entire activity is 1.00.

Demodex blepharitis (DB) is a common yet frequently underrecognized condition, often misdiagnosed as dry eye disease or meibomian gland dysfunction, leading to delayed treatment and increased patient burden. Clinicians need improved recognition of hallmark signs such as collarettes, along with a clearer understanding of the limitations of traditional therapies and the role of newer evidence-based options like lotilaner. Enhancing diagnostic accuracy, individualized treatment selection, and structured follow-up can improve adherence and long-term outcomes. Education focused on these strategies aims to reduce misclassification, optimize care, and improve quality of life for patients with DB.

*Please stay tuned for additional content to this activity available for credit. The maximum amount of credit(s) available for the entire activity is 1.00.

Demodex blepharitis (DB) is a common yet frequently underrecognized condition, often misdiagnosed as dry eye disease or meibomian gland dysfunction, leading to delayed treatment and increased patient burden. Clinicians need improved recognition of hallmark signs such as collarettes, along with a clearer understanding of the limitations of traditional therapies and the role of newer evidence-based options like lotilaner. Enhancing diagnostic accuracy, individualized treatment selection, and structured follow-up can improve adherence and long-term outcomes. Education focused on these strategies aims to reduce misclassification, optimize care, and improve quality of life for patients with DB.

*Please stay tuned for additional content to this activity available for credit. The maximum amount of credit(s) available for the entire activity is 1.00.

This series of brief episodes examines Alzheimer’s disease (AD) as an integrated neurodegenerative and neuropsychiatric syndrome. Drs. Marwan Sabbagh and Dani Cabral highlight challenges in clinical phenotyping and the consequences of treating neuropsychiatric symptoms (NPS) as separate comorbidities. The faculty also review emerging therapeutic approaches, including tau-targeting therapy for Alzheimer’s disease, as well as novel treatments for agitation and related NPS.

*Please stay tuned for additional content to this activity available for credit. The maximum amount of credit(s) available for the entire activity is 0.50.

Demodex blepharitis (DB) is a common yet frequently underrecognized condition, often misdiagnosed as dry eye disease or meibomian gland dysfunction, leading to delayed treatment and increased patient burden. Clinicians need improved recognition of hallmark signs such as collarettes, along with a clearer understanding of the limitations of traditional therapies and the role of newer evidence-based options like lotilaner. Enhancing diagnostic accuracy, individualized treatment selection, and structured follow-up can improve adherence and long-term outcomes. Education focused on these strategies aims to reduce misclassification, optimize care, and improve quality of life for patients with DB.

*Please stay tuned for additional content to this activity available for credit. The maximum amount of credit(s) available for the entire activity is 1.00.

This series of brief episodes examines Alzheimer’s disease (AD) as an integrated neurodegenerative and neuropsychiatric syndrome. Drs. Marwan Sabbagh and Dani Cabral highlight challenges in clinical phenotyping and the consequences of treating neuropsychiatric symptoms (NPS) as separate comorbidities. The faculty also review emerging therapeutic approaches, including tau-targeting therapy for Alzheimer’s disease, as well as novel treatments for agitation and related NPS.

*Please stay tuned for additional content to this activity available for credit. The maximum amount of credit(s) available for the entire activity is 0.50.

Demodex blepharitis (DB) is a common yet frequently underrecognized condition, often misdiagnosed as dry eye disease or meibomian gland dysfunction, leading to delayed treatment and increased patient burden. Clinicians need improved recognition of hallmark signs such as collarettes, along with a clearer understanding of the limitations of traditional therapies and the role of newer evidence-based options like lotilaner. Enhancing diagnostic accuracy, individualized treatment selection, and structured follow-up can improve adherence and long-term outcomes. Education focused on these strategies aims to reduce misclassification, optimize care, and improve quality of life for patients with DB.

*Please stay tuned for additional content to this activity available for credit. The maximum amount of credit(s) available for the entire activity is 1.00.

This series of brief episodes examines Alzheimer’s disease (AD) as an integrated neurodegenerative and neuropsychiatric syndrome. Drs. Marwan Sabbagh and Dani Cabral highlight challenges in clinical phenotyping and the consequences of treating neuropsychiatric symptoms (NPS) as separate comorbidities. The faculty also review emerging therapeutic approaches, including tau-targeting therapy for Alzheimer’s disease, as well as novel treatments for agitation and related NPS.

*Please stay tuned for additional content to this activity available for credit. The maximum amount of credit(s) available for the entire activity is 0.50.

Demodex blepharitis (DB) is a common yet frequently underrecognized condition, often misdiagnosed as dry eye disease or meibomian gland dysfunction, leading to delayed treatment and increased patient burden. Clinicians need improved recognition of hallmark signs such as collarettes, along with a clearer understanding of the limitations of traditional therapies and the role of newer evidence-based options like lotilaner. Enhancing diagnostic accuracy, individualized treatment selection, and structured follow-up can improve adherence and long-term outcomes. Education focused on these strategies aims to reduce misclassification, optimize care, and improve quality of life for patients with DB.

*Please stay tuned for additional content to this activity available for credit. The maximum amount of credit(s) available for the entire activity is 1.00.

This series of brief episodes examines Alzheimer’s disease (AD) as an integrated neurodegenerative and neuropsychiatric syndrome. Drs. Marwan Sabbagh and Dani Cabral highlight challenges in clinical phenotyping and the consequences of treating neuropsychiatric symptoms (NPS) as separate comorbidities. The faculty also review emerging therapeutic approaches, including tau-targeting therapy for Alzheimer’s disease, as well as novel treatments for agitation and related NPS.

*Please stay tuned for additional content to this activity available for credit. The maximum amount of credit(s) available for the entire activity is 0.50.